Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BRAIN Biotech AG's enterprise value is €58.00 Mil.
BRAIN Biotech AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.80 Mil. Therefore, BRAIN Biotech AG's EV-to-EBITDA for today is -15.27.
The historical rank and industry rank for BRAIN Biotech AG's EV-to-EBITDA or its related term are showing as below:
HAM:BNN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -115.34 Med: -28.49 Max: 715.53
Current: -15.27
During the past 11 years, the highest EV-to-EBITDA of BRAIN Biotech AG was 715.53. The lowest was -115.34. And the median was -28.49.
HAM:BNN's EV-to-EBITDA is ranked worse than 100% of 1332
companies
in the Chemicals industry
Industry Median: 12.27
vs HAM:BNN: -15.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
BRAIN Biotech AG (HAM:BNN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BRAIN Biotech AG's PE Ratio (TTM) for today is calculated as:
BRAIN Biotech AG's share price for today is €2.73.
BRAIN Biotech AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.510.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for BRAIN Biotech AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, BRAIN Biotech AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG EV-to-EBITDA vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's EV-to-EBITDA falls into.
BRAIN Biotech AG's current Enterprise Value is €58.00 Mil.
BRAIN Biotech AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG (HAM:BNN) has a EV-to-EBITDA of -15.27 as of Aug. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BRAIN Biotech AG. According to the industry distribution chart, BRAIN Biotech AG ranks #999999 out of 1332 companies in the Chemicals industry.
Is BRAIN Biotech AG's EV-to-EBITDA too high?
BRAIN Biotech AG's current EV-to-EBITDA is -15.27. Based on the distribution chart, BRAIN Biotech AG ranks #999999 out of 1332 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BRAIN Biotech AG has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's EV-to-EBITDA compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #999999 out of 1332 companies for EV-to-EBITDA. This places BRAIN Biotech AG in the lower half of its industry. The industry median EV-to-EBITDA is 12.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Chemicals company?
The median EV-to-EBITDA among Chemicals companies is 12.27, based on 1,332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BRAIN Biotech AG. For the Chemicals industry, the median EV-to-EBITDA is 12.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current EV-to-EBITDA is -15.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Fairly Valued. The stock's GF Value™ is €2.64, compared to a current price of €2.73 — trading 3.4% above its estimated fair value. The current EV-to-EBITDA is -15.27. BRAIN Biotech AG's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current EV-to-EBITDA is -15.27 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.73 is trading 3.4% above its estimated GF Value™ of €2.64.
GuruFocus considers BRAIN Biotech AG to be Fairly Valued.
Key valuation signals for HAM:BNN:
EV-to-EBITDA: -15.27
GF Value™: €2.64 vs. price of €2.73 (3.4% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
66GF Score
Get the complete analysis for HAM:BNN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
